Regulatory Filings • Apr 28, 2015
Regulatory Filings
Open in ViewerOpens in native device viewer
Press Release Bagneux, France, Tuesday, April 28, 2015
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinicalstage specialty biopharmaceutical company, today announced that it has been selected by EnterNext, part of the Euronext exchange, to become a member of the Tech 40 Index tier.
Based on quantitative and qualitative criteria, this Euronext label is awarded on a yearly basis to the top 40 technology companies listed on the SME's* tier of the Euronext exchange.
DBV Technologies is developing Viaskin®, an innovative new approach to the treatment of allergies – a major public health issue that has been increasing in prevalence. DBV Technologies, incorporated in France in 2002, has developed a proprietary, worldwide-patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus considerably lowering the risk of a systemic, allergic reaction in the event of accidental exposure. DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies has designed two products candidates: Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation from the US Food and Drug Administration.
DBV Technologies shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and on the Nasdaq Stock Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com.
Nathalie Donne Director, Corporate Communication & Business Development Tél. : +33(0)1 55 42 78 72 [email protected]
Susanna Mesa VP Finance, US Investor Relations & Strategy Tél. : +1 917-346-3447 [email protected]
Marion Janic Rooney & Associates Tél. : +1-212-223-4017 [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.